Your browser is no longer supported. Please, upgrade your browser.
NRBO NeuroBo Pharmaceuticals, Inc. daily Stock Chart
NeuroBo Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-13.57 Insider Own2.68% Shs Outstand15.67M Perf Week1.22%
Market Cap111.68M Forward P/E- EPS next Y-0.69 Insider Trans0.00% Shs Float2.48M Perf Month-17.82%
Income-22.20M PEG- EPS next Q-0.19 Inst Own3.30% Short Float12.51% Perf Quarter-50.11%
Sales- P/S- EPS this Y90.50% Inst Trans5.11% Short Ratio4.43 Perf Half Y-39.11%
Book/sh0.49 P/B13.55 EPS next Y5.50% ROA-277.40% Target Price- Perf Year-56.46%
Cash/sh0.58 P/C11.40 EPS next 5Y- ROE-424.20% 52W Range5.95 - 30.00 Perf YTD-24.11%
Dividend- P/FCF- EPS past 5Y-33.90% ROI- 52W High-77.83% Beta0.70
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low11.76% ATR0.64
Employees12 Current Ratio3.00 Sales Q/Q- Oper. Margin- RSI (14)37.42 Volatility5.88% 8.84%
OptionableYes Debt/Eq0.00 EPS Q/Q36.70% Profit Margin- Rel Volume0.64 Prev Close6.64
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume69.90K Price6.65
Recom1.50 SMA20-8.37% SMA50-27.27% SMA200-40.31% Volume26,917 Change0.15%
Jun-15-20Initiated H.C. Wainwright Buy $20
Jun-16-20 04:05PM  
May-26-20 08:30AM  
May-20-20 04:29PM  
Apr-21-20 08:30AM  
Apr-16-20 04:22PM  
Apr-14-20 09:15AM  
Mar-31-20 11:04AM  
Mar-30-20 04:30PM  
Jan-13-20 09:00AM  
Jan-10-20 05:00PM  
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. Its therapeutics programs include NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.